International researchers have identified a surprising culprit behind glioblastoma's devastating lethality: circular DNA fragments that operate independently from normal chromosomes. These genetic renegades may hold the key to understanding why this brain cancer kills most patients within fourteen months despite decades of medical advances. The discovery challenges conventional thinking about how cancer develops.
Glioblastoma is the most aggressive form of brain cancer, with a median survival rate of just over a year. Standard treatments—surgery, radiation, and chemotherapy—have limited effectiveness, and the tumor often recurs. The newly identified circular DNA, known as extrachromosomal DNA (ecDNA), is found in a significant proportion of glioblastoma tumors. Unlike normal DNA, which is packaged into chromosomes, ecDNA exists as small, circular loops that can replicate rapidly and carry oncogenes that drive cancer growth.
Researchers from multiple institutions, including the University of California, San Diego, and the Salk Institute, analyzed tumor samples and found that ecDNA is present in about 40% of glioblastoma cases. These circular fragments can contain multiple copies of cancer-promoting genes, allowing the tumor to evolve quickly and resist treatment. The study, published in the journal Nature Genetics, suggests that ecDNA may be a key driver of the disease's aggressiveness.
As companies like CNS Pharmaceuticals Inc. (NASDAQ: CNSP) continue their quest for more effective treatments against glioblastoma, these findings could open new avenues for therapy. Understanding how ecDNA functions may lead to drugs that target these rogue rings, potentially disrupting the tumor's ability to adapt and grow. However, researchers caution that much more work is needed before such treatments become available.
The discovery also raises questions about the fundamental biology of cancer. For decades, scientists believed that cancer progression was driven primarily by mutations in chromosomal DNA. The presence of ecDNA suggests that cancer cells can acquire genetic changes through alternative mechanisms, which may explain why some tumors are so difficult to treat. This paradigm shift could influence how future cancer research is conducted.
The implications extend beyond glioblastoma. EcDNA has been found in other aggressive cancers, including breast, lung, and ovarian cancers. If researchers can develop methods to target ecDNA across multiple cancer types, it could have a broad impact on oncology. For now, the focus remains on understanding the basic biology of these circular DNA fragments and how they contribute to cancer progression.
The study was supported by grants from the National Institutes of Health and the American Cancer Society. The researchers have filed patent applications related to ecDNA detection and potential therapeutic targets.
